Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) – Leerink Swann issued their FY2019 earnings estimates for Ionis Pharmaceuticals in a research note issued to investors on Wednesday, Zacks Investment Research reports. Leerink Swann analyst P. Matteis anticipates that the company will post earnings of ($0.56) per share for the year.
WARNING: This piece was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2017/11/12/equities-analysts-offer-predictions-for-ionis-pharmaceuticals-inc-s-fy2019-earnings-ions.html.
Other analysts have also issued reports about the company. Morgan Stanley lifted their price objective on Ionis Pharmaceuticals from $45.00 to $49.00 and gave the stock an “equal weight” rating in a research report on Wednesday. Stifel Nicolaus reiterated a “hold” rating on shares of Ionis Pharmaceuticals in a research report on Tuesday, September 12th. Evercore ISI started coverage on Ionis Pharmaceuticals in a research report on Wednesday, August 16th. They set an “outperform” rating and a $65.00 target price for the company. Needham & Company LLC restated a “buy” rating and set a $64.00 target price on shares of Ionis Pharmaceuticals in a research report on Wednesday, July 26th. Finally, Jefferies Group LLC restated an “underperform” rating and set a $18.00 target price (up from $17.00) on shares of Ionis Pharmaceuticals in a research report on Thursday, August 10th. Three investment analysts have rated the stock with a sell rating, seven have issued a hold rating and six have issued a buy rating to the stock. Ionis Pharmaceuticals has an average rating of “Hold” and an average price target of $50.31.
Shares of Ionis Pharmaceuticals (IONS) opened at $55.88 on Thursday. The company has a quick ratio of 5.00, a current ratio of 6.25 and a debt-to-equity ratio of 1.50. The company has a market capitalization of $6,973.60, a PE ratio of 372.53 and a beta of 2.90. Ionis Pharmaceuticals has a 12-month low of $37.26 and a 12-month high of $65.51.
In other news, SVP Patrick R. O’neil sold 1,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $58.35, for a total transaction of $58,350.00. Following the sale, the senior vice president now owns 11,433 shares in the company, valued at approximately $667,115.55. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Stanley T. Crooke sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $52.00, for a total value of $780,000.00. Following the sale, the chief executive officer now owns 43,014 shares in the company, valued at approximately $2,236,728. The disclosure for this sale can be found here. Insiders sold a total of 98,636 shares of company stock worth $5,723,915 in the last 90 days. Company insiders own 2.13% of the company’s stock.
Several institutional investors have recently made changes to their positions in IONS. BlackRock Inc. raised its stake in shares of Ionis Pharmaceuticals by 37,569.7% during the 1st quarter. BlackRock Inc. now owns 6,559,808 shares of the company’s stock worth $263,704,000 after purchasing an additional 6,542,394 shares in the last quarter. State Street Corp raised its stake in shares of Ionis Pharmaceuticals by 20.5% during the 1st quarter. State Street Corp now owns 3,340,471 shares of the company’s stock worth $134,285,000 after purchasing an additional 567,792 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Ionis Pharmaceuticals by 4.4% during the 2nd quarter. Vanguard Group Inc. now owns 9,855,160 shares of the company’s stock worth $501,332,000 after purchasing an additional 417,364 shares in the last quarter. American Century Companies Inc. raised its stake in Ionis Pharmaceuticals by 33.0% in the 3rd quarter. American Century Companies Inc. now owns 1,144,526 shares of the company’s stock valued at $58,027,000 after acquiring an additional 284,266 shares during the period. Finally, First Trust Advisors LP raised its stake in Ionis Pharmaceuticals by 40.2% in the 3rd quarter. First Trust Advisors LP now owns 982,344 shares of the company’s stock valued at $49,805,000 after acquiring an additional 281,733 shares during the period. Institutional investors own 89.05% of the company’s stock.
Ionis Pharmaceuticals Company Profile
Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.
Get a free copy of the Zacks research report on Ionis Pharmaceuticals (IONS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.